A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects with Advanced Malignant Solid Tumour. Patients will be enrolled in two stages: a dose-escalation stage and a dose expansion stage.
Advanced Malignant Solid Tumours
DRUG: JS212 for Injection
DLT, Incidence and severity of DLT events, Up to 1 years|Incidence and severity of Adverse Events, Abnormal changes in clinical symptoms, vital signs, physical examination, laboratory tests, electrocardiograph and other examinations., Up to 2 years|MTD, Maximum tolerated dose, Up to 1 years|RP2D, Recommended phase II dose, Up to 1 years|ORR, Objective Response Rate (ORR) as Assessed by Investigator according to RECIST v1.1, Up to 2 years
DOR, Duration of Objective Response (DOR) as Assessed by Investigator according to RECIST v1.1, Up to 2 years|DCR, Investigator-assessed Duration of objective Response (DCR) according to RECIST v1.1, Up to 2 years|Progression-Free Survival (PFS), Progression-Free Survival (PFS) as Determined by Investigator according to RECIST v1.1, Up to 2 years|Overall Survival (OS), Overall Survival (OS), Up to 2 years|Pharmacokinetic (PK), Patient blood concentrations and pharmacokinetic parameters after drug administration, About 6 months after first dosing|Immunogenicity, Incidence of antidrug antibodies (ADA), About 6 months after first dosing
To explore the correlation between potential MARKERS and efficacy, To explore the correlation between potential MARKERS and efficacy, Up to 2 years|To explore the correlation between serum β-Glucuronidase Concentrations and efficacy, To explore the correlation between serum β-Glucuronidase Concentrations and efficacy, Up to 2 years
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects with Advanced Malignant Solid Tumour. Patients will be enrolled in two stages: a dose-escalation stage and a dose expansion stage.